In a move applauded by the health care industry, CMS has decided to hold off finalizing a proposal that would have required drug makers aggregate, or “stack,” all manufacturer price concessions to determine a final best price for a covered outpatient drug in Medicaid’s Drug Rebate Program (MDRP), including discounts, rebates or other arrangements made to different best price-eligible entities throughout the drug supply chain, the agency said Friday (May 17) in an update on a proposed rule related to...